Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Net Cash Flow: 2015-2025

Historic Net Cash Flow for Spyre Therapeutics (SYRE) over the last 11 years, with Sep 2025 value amounting to -$16.8 million.

  • Spyre Therapeutics' Net Cash Flow fell 164.22% to -$16.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$6.7 million, marking a year-over-year increase of 67.23%. This contributed to the annual value of -$99.8 million for FY2024, which is 165.32% down from last year.
  • According to the latest figures from Q3 2025, Spyre Therapeutics' Net Cash Flow is -$16.8 million, which was down 150.54% from $33.2 million recorded in Q2 2025.
  • In the past 5 years, Spyre Therapeutics' Net Cash Flow registered a high of $200.1 million during Q2 2023, and its lowest value of -$182.4 million during Q2 2024.
  • Moreover, its 3-year median value for Net Cash Flow was $17.9 million (2024), whereas its average is $2.6 million.
  • Its Net Cash Flow has fluctuated over the past 5 years, first crashed by 11,226.75% in 2023, then spiked by 30,582.54% in 2024.
  • Spyre Therapeutics' Net Cash Flow (Quarterly) stood at -$9.5 million in 2021, then spiked by 56.45% to -$4.1 million in 2022, then surged by 2,445.66% to $97.3 million in 2023, then slumped by 81.65% to $17.9 million in 2024, then plummeted by 164.22% to -$16.8 million in 2025.
  • Its Net Cash Flow stands at -$16.8 million for Q3 2025, versus $33.2 million for Q2 2025 and -$40.9 million for Q1 2025.